Cambrex Completes New Process and Analytical Development Facility at its Karlskoga, Sweden Manufacturing Site
June 04 2019 - 8:00AM
Cambrex Corporation (NYSE: CBM), the leading small molecule company
providing drug substance, drug product and analytical services
across the entire drug lifecycle, today announced that it has
completed a new 600 m2 facility at its site in Karlskoga, Sweden,
which incorporates new laboratories for process and analytical
development.
The new, three-story building will incorporate
process technology, QC and analytical development laboratories. The
process technology laboratories will expand capacity providing an
area where R&D and production teams can work together on scale
up demonstration and technology transfer, including new
capabilities in the scaling up of potent molecules requiring
containment. The facility will employ computer modeling to
optimize reactor set ups and plant conditions to improve technology
transfer and the performance of existing processes.
The laboratory also includes high pressure
reaction vessels and crystallization equipment to optimize drug
substance manufacturing, as well as expanding the temperature range
at which reactions can be carried out, with vessels to handle
conditions from cryogenic to nearly 200 degrees Celsius. The new QC
and analytical development laboratories increase the capacity and
capabilities for handling in-process and raw material analysis.
To support the site’s recent growth, which has
included the expansion of large scale manufacturing capacity, a new
$6 million, 3,000 m2 logistics center has also been completed and
opened. This includes a fully cGMP-compliant warehouse with
integral temperature monitoring and control, and has the capacity
for 4,500 pallets.
“This expansion and investments we have made at
Karlskoga are part of an ongoing strategic program to ensure it has
the flexibility, capacity and capabilities to meet the evolving
needs of the market and industry,” commented Bjarne Sandberg,
Managing Director, Cambrex Karlskoga. “The new technical laboratory
will act as a hub for the company’s engineers, operators and
chemists to ensure smooth scale up and handover of processes from
development sites across our global network.”
Cambrex’s site in Karlskoga employs over 400
people and features a wide range of flexible manufacturing
facilities including 4 cGMP pilot plants and 7 full scale
commercial production units.
About CambrexCambrex is the leading small
molecule company that provides drug substance, drug product and
analytical services across the entire drug lifecycle. The company
provides customers with an end-to-end partnership for the research,
development and manufacture of small molecule therapeutics. With
over 35 years’ experience and a growing team of over 2,000 experts
servicing global clients from sites in North America and Europe,
Cambrex is a trusted partner in branded and generic markets for API
and dosage form development and manufacturing.
Cambrex offers a range of specialist drug
substance technologies and capabilities including biocatalysis,
continuous flow, controlled substances, solid state science,
material characterization and highly potent APIs. In addition,
Cambrex can support conventional dosage forms including oral
solids, semi-solids and liquids and has the expertise to
manufacture specialist dosage forms such as modified-release, fixed
dose combination, pediatric, bi-layer tablets, stick packs,
topicals, controlled substances, sterile and non-sterile
ointments.
For more information, please visit
www.cambrex.com
Contact:Alex
Maw
Director, Marketing and
Communications
Tel: +44 7803 443
155
Email: alex.maw@cambrex.com
Cambrex (NYSE:CBM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cambrex (NYSE:CBM)
Historical Stock Chart
From Jul 2023 to Jul 2024